183 patents currently held
8 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Dec 2030. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
1
Ending by 2030
Dec 2030
Next term end
79
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Mar 2032 · Medium confidence
Also notable
Ends no later than Jun 2032 · Low confidence
Also notable
Ends Feb 2033 · High confidence
Liver Specific Delivery of Messenger RNA
US 10,143,758
The most cited patent in this portfolio, cited by 261 later US patents, top 1% of utility patents granted in 2018 in our data. Protection runs to 2032.
Mrna Therapy for Fabry Disease
US 9,308,281
Cited by 125 later US patents, top 5% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2032. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Cleavable Lipids
US 9,717,690
Cited by 147 later US patents, top 5% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 23, 2026The maintenance fee for mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES (US 9,061,021) comes due Dec 23, 2026. Unpaid by Jun 23, 2027, it lapses early.
- 2 fees due Jan 4 to 16, 2027 · next Jan 4
- 2 fees due Feb 1 to 22, 2027 · next Feb 1
- 2 fees due Mar 17 to 24, 2027 · next Mar 17
- 2 fees due Apr 1 to 17, 2027 · next Apr 1
- 3 fees due May 10 to 21, 2027 · next May 10
- 4 fees due Jun 3 to 17, 2027 · next Jun 3
- 1 fee due Jul 30, 2027The maintenance fee for Methods for Purification of Messenger RNA (US 11,884,692) comes due Jul 30, 2027. Unpaid by Jan 31, 2028, it lapses early.
- 1 fee due Aug 6, 2027The maintenance fee for Lipid Formulations for Delivery of Messenger RNA (US 11,890,377) comes due Aug 6, 2027. Unpaid by Feb 7, 2028, it lapses early.
- 3 fees due Sep 3 to 10, 2027 · next Sep 3
- 7 fees due Oct 9 to 30, 2027 · next Oct 9
- 3 fees due Nov 7 to 12, 2027 · next Nov 7
Recent changes
- Oct 15Assignment recorded on 1 record: Translate Bio Ma, Inc. to Translate Bio, Inc. Recorded Oct 15, 2026, executed Oct 14, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76384, frame 774.
- 8 of the patents on this record were granted since Aug 17, 2026
What they patent
The 5 largest of its 79 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Mrna Therapy for Fabry Disease | 17 in force | to Jun 2032 |
| Biodegradable Lipids for Delivery of Nucleic Acids | 7 in force | to May 2035 |
| Methods for Purification of Messenger RNA | 6 in force | to Sep 2036 |
| Ionizable Cationic Lipids | 6 in force | to Aug 2035 |
| CFTR Mrna Compositions and Related Methods and Uses | 5 in force | to Mar 2036 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,576,166 | Liver Specific Delivery of Messenger RNA In force · Medium confidence | In force | Medium confidence | |
| US 8,853,377 | Mrna for Use in Treatment of Human Genetic Diseases In force · High confidence | In force | High confidence | |
| US 9,061,021 | mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES In force · Medium confidence | In force | Medium confidence | |
| US 9,956,271 | mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES In force · High confidence | In force | High confidence | |
| US 11,135,274 | mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES In force · Medium confidence | In force | Medium confidence | |
| US 10,143,758 | Liver Specific Delivery of Messenger RNA In force · Medium confidence | In force | Medium confidence | |
| US 11,224,642 | Mrna Therapy for Argininosuccinate Synthetase Deficiency In force · High confidence | In force | High confidence | |
| US 9,308,281 | Mrna Therapy for Fabry Disease In force · Low confidence | In force | Low confidence | |
| US 9,597,413 | Pulmonary Delivery of Mrna In force · Low confidence | In force | Low confidence | |
| US 10,238,754 | Lipid Nanoparticle Compositions and Methods for Mrna Delivery In force · Low confidence | In force | Low confidence |
Also on record, not counted in the 183: 8 patents in force now held by others · 67 applications pending · 47 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.